In the “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes” (SUSTAIN-6) trial [94], there was a 36% decrease in new or worsening nephropathy with the injectable GLP-1 receptor agonist semaglutide. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.